Authors

Latest:

Dr. Phan Discusses Challenges With Treating pNETs

Alexandria Phan, MD, the director of GI Medical Oncology at Houston Methodist, discusses some of the challenges oncologists face with treating patients with pancreatic neuroendocrine tumors (pNETs).

Alexey V. Danilov, MD, PhD

Latest:

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

Drs Danilov and O'Brien discuss updates with acalabrutinib, zanubrutinib, and pirtobrutinib in CLL that were presented at the 2024 ASH Annual Meeting.

Alexey V. Danilov, MD, PhD, Oregon Health & Science University

Alexey V Danilov, MD, PhD, University School of Medicine in Portland, Oregon

Alexis E. Horace, PharmD

Latest:

The Future of Melanoma Treatment

Drugs currently approved by the FDA for treatment of melanoma include aldesleukin, dabrafenib, dacarbazine, ipilimumab, trametinib, and vemurafenib. This article will explore pharmacologic agents currently being investigated for the treatment of melanoma.

Alfred L. Garfall, MD, Abramson Cancer Center

Latest:

CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond

Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.

Alfred L. Garfall, MD, MS

Alfred L. Garfall, MD, MS, is an associate professor of medicine (hematology-oncology) and director of the Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program at Hospital of the University of Pennsylvania. He is also section chief of Multiple Myeloma in the Division of Hematology/Oncology, in the Department of Medicine, at Perelman School of Medicine, of University of Pennsylvania.

Latest:

Dr Garfall on the Potential Role for Consolidation or Maintenance CAR T-Cell Therapy in Myeloma

Alfred Garfall, MD, discusses the potential role of CAR T-cell therapy in multiple myeloma either as consolidation or maintenance in the up-front setting.

Alfredo Addeo, MD

Latest:

Dr. Addeo Discusses the Need for Biomarkers in NSCLC

Alfredo Addeo, MD, consultant medical oncologist, University Hospital of Geneva, discusses the need for effective biomarkers in non–small cell lung cancer.

Ali McBride, PharmD, MS, BCOP

Latest:

Dr. McBride on Biosimilar Rituximab

Ali McBride, PharmD, MS, BCOP, discusses the oncology community’s reaction to biosimilars for rituximab (Rituxan).

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA

Latest:

Dr. McBride on the Potential of Biosimilars in Oncology

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, discusses the potential utility of biosimilars in oncology.

Ali McBride, PharmD, MS, BCPS

Latest:

Dr. McBride on the Excitement With Oral Oncolytics

Ali McBride, PharmD, MS, BCPS, clinical coordinator, Hematology/Oncology, secretary, Association of Community Cancer Centers (ACCC), discusses the importance with and excitement of oral oncolytics.

Ali Sadoughi, MD

Latest:

"Ultrathin" Bronchoscopy Improves Care for Patients With Lung Nodules

To spare patients from surgery or other unnecessary procedures, Montefiore Einstein Center for Cancer Care developed an advanced method of bronchoscopy that provides peace of mind for individuals with lung nodules. The minimally invasive bronchoscopy provides a very safe method of biopsy, importantly at very early stages when the nodules are relatively small.

Alice Beers, RN, BSN, OCN, MedStar Health System

Alice Goodman

Latest:

Small Renal Masses in Elderly Can Be Managed by Surveillance

Small renal masses identified in elderly patients can be safely managed by surveillance and maintain the same mortality risk as those who undergo surgery, suggesting that surgery could be avoided altogether in many patients.

Alice Mims, MD

Latest:

Dr. Mims on FDA Approval of Ivosidenib in Patients With AML

Alice Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of the IDH1m inhibitor ivosidenib for the treatment of patients with acute myeloid leukemia (AML).

Alice S. Mims, MD

Latest:

Dr. Mims on the Beat AML Master Trial in AML

Alice S. Mims, MD, discusses the Beat AML Master Trial in acute myeloid leukemia (AML).

Alice Shaw, MD, PhD, Harvard Medical School

Alice T. Shaw, MD, PhD

Latest:

Dr. Shaw on Sequencing Strategies in ALK-Positive NSCLC

Alice T. Shaw, MD, PhD, associate professor of medicine at Harvard Medical School, director of Thoracic Oncology and Paula O’Keefe Endowed Chair in Thoracic Oncology at Massachusetts General Hospital, discusses sequencing strategies in ALK-positive non–small cell lung cancer (NSCLC).

Alice T. Shaw, MD, PhD, Massachusetts General Hospital

Alice Ulhoa-Cintra, MD

Latest:

Using QOPI to Improve Quality Within Your Fellowship Program

The QOPI program creates a uniform measurement of the quality of care delivered by an oncologist; this affords self-examination and directed improvement of practices.